Advertisement
Advertisement
U.S. markets open in 7 hours 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Moleculin Biotech, Inc. (MBRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9700-0.1200 (-5.74%)
At close: 04:00PM EST
1.9900 +0.02 (+1.02%)
After hours: 07:42PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close2.0900
Open2.1200
Bid0.0000 x 2200
Ask0.0000 x 1000
Day's Range1.9400 - 2.1300
52 Week Range1.9400 - 8.7800
Volume508,087
Avg. Volume232,580
Market Cap56.297M
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-0.7000
Earnings DateNov 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MBRX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Moleculin Biotech, Inc.
    Daily – Vickers Top Insider Picks for 12/03/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • PR Newswire

    Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

    Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the Company's Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. With this IND now cleared, Moleculin plans to initiate a Phase 1 open label, single arm,

  • PR Newswire

    Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event

    Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Kemp, Founder, President, CEO and Chairman and Dr. John Paul Waymack, Senior Chief Medical Officer will participate in the Virtual Investor Roundtable Event on Thursday, November 18, 2021 at 11:00 AM ET.

  • PR Newswire

    Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update

    Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin, we or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.

Advertisement
Advertisement